Loading…
Disclosed for 94 months, Dec 2018 to Sep 2026.
DSP Healthcare Fund is an active equity fund in the Sectoral / Thematic category from DSP Mutual Fund. In December 2021 it disclosed 24 stocks worth ₹1,442 Cr, up ₹55.4 Cr from Nov 2021. Its largest positions were Sun Pharmaceutical Industries Limited (11.9%), Max Healthcare Institute Limited (8.7%), Cipla Limited (8.0%); the ten largest together made up 67.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 52.7% of its equity. Cash and debt stood at 3.7%. Compared with Nov 2021 the fund entered 2 new stocks and exited 1.
Top-10 weight is higher than 92% of peers
Holds more stocks than 7% of peers
Holds more cash than 53% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against Nov 2021. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 11.93% | up 0.87 pts | ₹172 Cr | up ₹18.7 Cr | Added |
| Max Healthcare Institute Limited | 8.66% | up 0.68 pts | ₹125 Cr | up ₹14.2 Cr | Added |
| Cipla Limited | 7.96% | down 0.56 pts | ₹115 Cr | down ₹3.3 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 6.89% | down 1.24 pts | ₹99.4 Cr | down ₹13.4 Cr | Trimmed |
| IPCA Laboratories Limited | 5.93% | down 0.05 pts | ₹85.5 Cr | up ₹2.6 Cr | Added |
| Procter & Gamble Health Limited | 5.88% | down 0.22 pts | ₹84.7 Cr | up ₹22 L | Held |
| Dr. Reddy's Laboratories Limited | 5.70% | up 0.05 pts | ₹82.2 Cr | up ₹3.9 Cr | Added |
| Lupin Limited | 5.67% | up 0.18 pts | ₹81.7 Cr | up ₹5.7 Cr | Added |
| Alkem Laboratories Limited | 4.22% | down 0.13 pts | ₹60.9 Cr | up ₹51 L | Added |
| Vijaya Diagnostic Centre Limited | 4.12% | down 0.12 pts | ₹59.4 Cr | up ₹61 L | Added |
| Cash, TREPS & receivables | 3.67% | up 2.65 pts | ₹52.9 Cr | up ₹38.8 Cr | Added |
| Indoco Remedies Limited | 3.54% | up 0.39 pts | ₹51 Cr | up ₹7.4 Cr | Added |
| Intuitive Surgical Inc | 3.52% | up 0.11 pts | ₹50.7 Cr | up ₹3.5 Cr | Added |
| Narayana Hrudayalaya Limited | 2.80% | down 0.03 pts | ₹40.4 Cr | up ₹1.2 Cr | Added |
| Globus Medical Inc | 2.51% | up 0.19 pts | ₹36.1 Cr | up ₹4.1 Cr | Added |
| Abiomed Inc | 2.49% | up 0.17 pts | ₹35.9 Cr | up ₹3.8 Cr | Added |
| ICICI Lombard General Insurance Company Limited | 2.35% | down 0.16 pts | ₹33.8 Cr | down ₹87 L | Trimmed |
| Abbott Laboratories | 2.31% | up 0.11 pts | ₹33.2 Cr | up ₹2.7 Cr | Added |
| Syngene International Limited | 2.00% | down <0.01 pts | ₹28.8 Cr | up ₹1.1 Cr | Added |
| Aarti Drugs Limited | 1.77% | up 0.65 pts | ₹25.5 Cr | up ₹10 Cr | Added |
| Alembic Pharmaceuticals Limited | 1.51% | down 0.07 pts | ₹21.8 Cr | down ₹13 L | Trimmed |
| MedPlus Health Services Limited | 1.38% | up 1.38 pts | ₹19.9 Cr | up ₹19.9 Cr | New |
| Kovai Medical Center and Hospital Limited | 1.17% | down 0.02 pts | ₹16.9 Cr | up ₹43 L | Added |
| Unichem Laboratories Limited | 1.13% | up 0.13 pts | ₹16.3 Cr | up ₹2.5 Cr | Added |
| Illumina Inc | 0.48% | up 0.48 pts | ₹6.9 Cr | up ₹6.9 Cr | New |
| Global X Funds - Global X Genomics & Biotechnology ETF Fund units | 0.44% | up 0.44 pts | ₹6.3 Cr | up ₹6.3 Cr | New |
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Nov 2021, the weight rose most in Retailing (+1.4 pts) and Pharmaceuticals (+0.9 pts), and fell most in Pharmaceuticals & Biotechnology (−3.6 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Dec 2018 | Dec 2020 | Jun 2021 | Sep 2021 | Nov 2021 | Dec 2021 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 69.9% | 65.8% | 62.2% | 59.2% | 56.3% | 52.7% |
| Healthcare Services | 16.6% | 20.4% | 22.2% | 25.7% | 29.0% | 29.8% |
| Pharmaceuticals | 10.7% | 6.6% | 6.8% | 6.6% | 6.4% | 7.3% |
| Healthcare Equipment & Supplies | — | 3.6% | 6.0% | 5.9% | 5.8% | 6.3% |
| Insurance | 2.7% | 3.6% | 2.8% | 2.6% | 2.5% | 2.4% |
| Retailing | — | — | — | — | — | 1.4% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| Jun 2026 |
| ₹3,514 Cr |
| 28 |
| 1 |
| 1 |
| 6.8% |
| 6.8% |
| — |
| May 2026 | ₹3,309 Cr | 28 | 0 | 2 | 6.3% | 6.3% | — |
| Apr 2026 | ₹3,142 Cr | 30 | 0 | 0 | 2.4% | 2.4% | — |
| Mar 2026 | ₹2,892 Cr | 30 | 0 | 0 | 1.5% | 1.5% | — |
| Feb 2026 | ₹3,033 Cr | 30 | 0 | 0 | 1.1% | 1.1% | — |
| Jan 2026 | ₹2,971 Cr | 30 | 0 | 1 | 1.2% | 1.2% | — |
| Dec 2025 | ₹3,114 Cr | 31 | 2 | 0 | 1.0% | 1.0% | — |
| Nov 2025 | ₹3,179 Cr | 29 | 0 | 0 | 2.1% | 2.1% | — |
| Oct 2025 | ₹3,144 Cr | 29 | 0 | 0 | 1.3% | 1.3% | — |
| Sep 2025 | ₹3,074 Cr | 29 | 0 | 0 | 2.0% | 2.0% | — |
| Aug 2025 | ₹3,107 Cr | 29 | 0 | 0 | 2.2% | 2.2% | — |
| Jul 2025 | ₹3,190 Cr | 29 | 0 | 0 | 1.8% | 1.8% | — |
| Jun 2025 | ₹3,057 Cr | 29 | 0 | 1 | 1.1% | 1.1% | — |
| May 2025 | ₹2,961 Cr | 30 | 0 | 0 | 0.4% | 0.4% | — |
| Apr 2025 | ₹2,912 Cr | 30 | 0 | 0 | 0.1% | 0.1% | — |
| Mar 2025 | ₹3,019 Cr | 30 | 0 | 1 | 0.8% | 0.8% | — |
| Feb 2025 | ₹2,951 Cr | 31 | 0 | 0 | 1.7% | 1.7% | — |
| Jan 2025 | ₹3,198 Cr | 31 | 1 | 0 | 0.8% | 0.8% | — |
| Dec 2024 | ₹3,340 Cr | 30 | 1 | 0 | 2.5% | 2.5% | — |
| Nov 2024 | ₹3,249 Cr | 29 | 0 | 0 | 4.8% | 4.8% | — |
| Oct 2024 | ₹3,138 Cr | 29 | 1 | 0 | 2.7% | 2.7% | — |
For any of the 70 earlier months, choose it in “Portfolio as of” at the top of the page.